http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2878077-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_456c4ed557172fb1009222912fdd3f5d |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J41-0005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J41-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate | 2015-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e66e5779a271ebd5f91ad87655207ad |
| publicationDate | 2021-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2878077-T3 |
| titleOfInvention | Procedures and compositions for the stimulation of the intestinal entero-endocrine system for the treatment of diseases or conditions related thereto |
| abstract | A composition comprising a pharmaceutically acceptable grade of at least one aminosterol, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of a condition or disorder that benefits from stimulation of the GI Response induced by Aminosterol in a subject, and wherein the condition or disorder is related to the nervous system and could benefit from neuroprotection, wherein: (a) the use comprises oral administration of the composition; and (b) the at least one aminosterol, or a pharmaceutically acceptable salt thereof, is present in the composition in a dose sufficient to produce a beneficial neuroprotective effect in the subject; (c) the aminosterol is squalamine or a salt thereof or Aminosterol 1436 or a salt thereof; and d) the nervous system related condition or disorder is Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, acute traumatic injury to the central nervous system, stroke, spinal cord injury, degenerative processes associated with aging, dementia of age, cerebral palsy, epilepsy, peripheral sensory neuropathy, depression or autism, |
| priorityDate | 2014-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 795.